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Mice of inbred laboratory strains differ in their susceptibility to lymphoma
induction by viruses, chemical carcinogens, and ionizing radiation (1-5). In the
case of retrovirus-induced lymphoma, a variety of genetically determined traits
can confer relative resistance to lymphomagenesis; these factors include H-2 type
(reviewed in reference 6), endogenous expression of viral envelope proteins (7),
and the as yet unidentified product of the Fv-1 locus (8, 9). The genetic factors
affecting resistance to lymphoma induction by percutaneous treatment with the
hydrocarbon carcinogen, 3-methylcholanthrene (MCA), are less well understood .
One such factor is inducibility for the enzyme aryl hydrocarbon hydroxylase
(AHH) (10). In AHH-inducible mice, MCA treatment gives rise to skin tumors
but not to lymphomas; by contrast, AHH-noninducible mice show a very weak
skin tumor response to the treatment, but they vary widely in a strain-specific
manner in their lymphoma response (2) . In genetic studies of AHH-noninducible
mouse strains, F, crosses of lymphoma-resistant X-susceptible strains show that
resistance to MCA-induced lymphoma is the dominant phenotype, and (FI X-
susceptible) backcross populations show incidences of MCA-induced lymphoma
suggestive of single-gene determination of resistance (11) .
We now report the results ofexperiments designed to show whether this AHH-
independent resistance mechanism acts at the level of bone marrow precursors
that ultimately give rise to the lymphoma cells, or if the environment in which
the marrow cells develop is the determinant of resistance. For this purpose we
have observed the response to MCA of radiation chimeras produced by replace-
ment of the bone marrow of susceptible or resistant hosts with that from donors
of the opposite phenotype. Our findings indicate that resistance to MCA lym-
phomagenesis is largely a phenotype of the bone marrow cells themselves rather
than of the host environment.
Materials and Methods
Mice.
￿
RF/J mice (H-2'°, Th~-1 .1) were obtained from The Jackson Laboratory, Bar
Harbor, ME. ST/bN mice (H-2 , Thy-1 .2) and (ST X RF)F, mice were bred in our colony
using ST/bN breeders obtained from the National Institutes of Health, Bethesda, MD.
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Chimeras.
￿
Chimeras were produced by irradiating 4-6-wk-old female recipients with
950 rad in a cesium irradiator. Donor mice were 6-16 wk old. Both male and female
mice were used as donors, although marrow for any single experiment was derived from
mice of one sex. The sex of marrow donors was found not to affect the lymphoma
incidence observed in the recipients (data not shown). Marrow was removed from donor
femurs by flushing the marrow cavity with balanced salt solution (BSS) containing 2%
FCS. The marrow was treated with either anti-Thy-1 .1 (in the form ofserum from a nude
mouse subcutaneously injected with the hybridoma 19E12, courtesy of Dr. M . Lostrom,
Genetics Systems, Seattle, WA), anti-Thy-1 .2 (serum from a nude mouse bearing the
hybridoma 6-68, obtained from Dr. U. Hammerling, Memorial Sloan-Kettering Cancer
Center, New York), or a combination of the two when F, marrow was treated. The
antiserum was diluted 1 :500, and the marrow cells were incubated in it for 20 min on ice .
After washing in BSS with 2% FCS, the cells were treated with a 1 :10 dilution of normal
rabbit serum as a source ofcomplement (Accurate Chemical & Scientific Corp., Westbury,
NY) for 45 min at 37°C . This antibody and complement treatment was repeated, the
cells were washed twice in BSS with 2% FCS, sus?ended in PBS with 2% FCS, and injected
intravenously into recipients. 5 x 106 to 1 X 10 cells were given to each recipient. Mice
were kept in filter-top cages for 3 wk after marrow transfer, and in some cases were given
tetracycline in their drinking water for 1 wk. Chimeras are designated by placing the
donor strain before an arrow, and the recipient strain after it, e.g., RF --) . ST.
Carcinogen Treatment.
￿
12-wk-old mice were treated percutaneously with a 1 % solution
of MCA (Fluka, Ronkonkoma, NY) in benzene (3). Their backs and flanks were shaved
before the first treatment; five daily treatments were given. Control mice were painted
with benzene alone. Lymphomatous animals were diagnosed by enlarged lymph nodes or
hunched posture and labored breathing, and were killed and autopsied. They were
examined particularly for enlargement of the spleen, lymph nodes, and thymus.
Immunofluorescence.
￿
Thymocytes were assayed for their Thy-1 phenotype by immu-
nofluorescence. Thymic biopsy was performed on 8-9-wk-old chimeras by sedating them
with sodium pentobarbital and removing a portion of the thymus by suction into a glass
pipette. In other cases the thymus was dissected out on autopsy. Cells were obtained by
teasing the tissue into a solution of PBS with 2% FCS. Aliquots of 3 X 106 cells were
stained according to published technique (12). The anti-Thy-1 reagents described above
were used at a dilution of 1 :1,000, with fluoresceinated goat anti-mouse Ig (Cooper
Biomedical, Malvern, PA) used as the second-step reagent.
Results and Discussion
In initial experiments we performed reciprocal bone marrow transfers using
the RF and ST/b strains; 80-90% of RF mice develop lymphoma by 6 mo after
carcinogen treatment, while ST/b show only a 15% frequency in the same time
span. These strains have the further advantage of being identical at the H-2
locus, which minimizes problems of histocompatibility in making chimeras.
Finally, they differ at the Thy-1 locus, so T cells in chimeras can be typed to
ascertain whether marrow engraftment was successful and whether lymphomas
derived from donor or host cells. However, preliminary work showed that
chimeras made using ST/b recipients, while surviving marrow transfer, could
not withstand treatment with MCA . For this reason (ST X RF)F, animals were
used instead of pure strain ST/b; as resistance to MCA leukemogenesis is
dominant, these mice show only a 30% incidence of lymphoma after MCA
treatment, and the same H-2 and Thy-l-related advantages apply. Results are
shown, however, for the viable ST -+ RF chimeras made in early experiments.
Table I summarizes the survival of chimeras before and after MCA treatment.
The overall rate of survival within the 2 mo after marrow transfer was 73%,
with RF recipients being somewhat more fragile than their (ST X RF)F, coun-ISHIZAKA AND LILLY
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TABLE I
Chimera Viability and Thy-1 Phenotypes
* Chimeras are designated by placing the name of the bone marrow donor strain before the arrow, and the name
ofthe recipient strain after the arrow.
$ The number of mice surviving at the time of MCA treatment, or 2 mo after marrow transfer.
Thymic biopsy was performed, and immunofluorescence was used to stain the cells obtained.
Immunofluorescence was performed on thymoctyes obtained at the time of killing at 270 d of age, or 6 months
after MCA treatment.
terparts. Animals treated with MCA, as opposed to benzene-treated or untreated
controls, did show increased mortality from causes other than lymphoma, but
only 17% of MCA-treated animals fell into this categoryand were excluded from
our data. Thus the animals included in the study do not constitute an unusually
sturdy minority population .
Fig. 1 summarizes the incidences oflymphoma in different groups ofchimeras.
Fig. 1 a showslymphoma-susceptible RF marrow developingunder threeseparate
circumstances: under normal conditions in an unmanipulated RF mouse, after
transfer into a syngeneic RFanimal, and aftertransfer into a lymphoma-resistant
(ST X RF)F1 animal. It is clear that the rate of lymphoma development after
MCAtreatment was similar regardless ofthe milieu in which the marrow matured
and was exposed to carcinogen. In the case of the RF marrow, there was a
roughly20% "background" oflymphoma occurring in untreated chimeras, which
increased to 50% in benzene-treated chimeras after a protracted latent period.
This may be due to accelerated development of the spontaneous T cell lympho-
mas seen in normal RF mice after 9 mo of age (2). The comparatively early
spontaneous cases may result from the stresses of transfer and repopulation on
the marrow. In any case, it is important to note that even these background rates
were similar whether the RF cells matured in a lymphoma-sensitive or -resistant
stroma.
Fig. 1 b shows the reciprocal transfer of resistant (ST X RF)F1 marrow into
susceptible RF mice. Once again, the incidence oflymphoma was not significantly
altered by the environment in which the marrow developed and was exposed to
carcinogen. Fig. 1 c presents similar data for ST -* RF chimeras. Like the
resistant (ST X RF)F 1 marrow, pure strain ST/b marrow did not show increased
susceptibility to lymphoma when it matured in an RF animal.
Statistic
RF --, RF RF ~ (ST x RF)
Chimera type*
(ST X RF) -+ RF (ST x RF) ~
(ST X RF) ST -, RF Total
Number made 67 52 62 28 51 260
Number surviving= 44 43 40 28 34 189
Percent survival 66 83 65 100 67 73
Number dying of causes
other than lymphoma:
MCA-treated 5/22 6/27 2/26 0/18 7/23 20/116
Benzene-treated 1/14 0/9 1/7 0/6 0/6 2/42
Control 0/8 0/7 2/7 0/4 1/3 3/29
Number with donor Thy-1
phenotype:
Before treatmentl - - 8/8 - - 4/4 12/12
After treatment:'
With lymphoma - 9/10 10/12 - 1/4 20/26
Without lym- - 5/5 7/8 - 5/6 17/19
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FIGURE I . Incidences of lymphoma among MCA-treated chimeras. Chimeras were con-
structed andtreated as described.Percentmortality refers only to animals dying of lymphoma;
animals dying of other causes were excluded from these data. The number of chimeras in
each experimental group is given in Table I. (a) RF (susceptible) marrow maturing in situ or
in (ST x RF)Fj or RF recipients. ForMCA-treated RF mice, n = 17. (b)(ST x RF)Ft (resistant)
marrow maturing in situ or in RF or (ST x RF)Fj recipients. For MCA-treated (ST x RF)F,
mice, n = 42. (c) ST/b marrow maturing in situ or in RF recipients. For MCA-treated ST/b
mice, n = 25.ISHIZAKA AND LILLY
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To ensure that we were measuring true rates of lymphoma developing from
donor marrow, a number ofanimals were tested for their Thy-1 phenotype upon
sacrifice. The resulting data (Table I) show that most animals developed lympho-
mas of donor rather than host marrow origin. Only 14% of the animals tested
showed an inappropriate lymphoma Thy-1 phenotype; a significant portion of
these were ST -* RF animals treated with MCA. This observation underscores
the disparity in sensitivity to MCA lymphomagenesis of RF and ST/b bone
marrow; although the vast majority of cells in an ST -* RF thymus at 4 wk after
transfer were of the ST/b Thy-1.2 phenotype, three of four lymphomas devel-
oping after MCA treatment originated from the minority RF population. This
constitutes evidence that extracellular factors produced by lymphoma-resistant
marrow-derived cells do not affect the susceptibility of marrow-derived cells
from a sensitive strain present in the same chimera.
Our results indicate that, in this instance of genetically determined resistance
to lymphoma, marrow does not alter its phenotype when it matures and is
exposed to carcinogen in the stroma ofa mouse ofthe opposite phenotype. This
finding has a number of implications bearing on possible mechanisms of lym-
phomagenesis and lymphoma resistance. For example, one might hypothesize
that RF and ST/b mice, although both AHH-noninducible, differ in the activity
of some enzyme involved in MCA processing. Our data indicate that any such
difference would have to reside in the marrow-derived target cell itself; resistance
to lymphomagenesis cannot involve differential metabolism of carcinogen by
stromal cells alone, since susceptible RF stroma does not confer susceptibility on
resident (ST X RF)F, marrow.
An alternative hypothesis is that MCA treatment induces lymphoma by the
intermediary ofan endogenous lymphomagenic retrovirus, and these strains are
not equally capable of generating such a virus after MCA treatment. The
precedent for this possibility is set by the AKR strain that has a high incidence
of spontaneous leukemia of viral etiology (13). To date no evidence of viral
involvement in MCA-induced RF lymphoma has been found (14). However, if
virus is responsible for MCA-induced lymphoma, the resistance of ST/b mice
cannot be due to failure of stromal cells to release virus. It would instead have
to be caused by the inability of a marrow-derived cell to release virus or to
becomereinfected. This findingdiffers from those on endogenous virus-induced
spontaneous AKR lymphomas, where prelymphomatous changes in chimeric
animals, appeared to depend on stromal phenotype rather than marrow origin
(15).
Finally, if the difference between susceptible and resistant strains lies in the
immune response to tumor cells, it cannot be due to an aspect of immune
response that would be altered by maturation in an allogeneic environment.
Such an immune response gene would have to map outside the MHC, as
resistance is not linked to the H-2 complex in backcross mice (12). Any such
difference would have to be a property intrinsic to the responding cells.
Summary
Reciprocal bone marrow tranfers were performed between mouse strains
sensitive or resistant to 3-methylcholanthrene-induced thymic lymphoma. Sensi-570
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tivity and resistance are properties inherent in bone marrow, and cannot be
altered by maturation of marrow in an environment of the opposite phenotype.
Receivedfor publication 3 March 1987 and in revisedform 21 May 1987.
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